Galectin Therapeutics assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Galectin Therapeutics (GALT) with a Buy rating and $6 price target Galectin’s lead asset is belapectin, an intravenously administered galectin-3 inhibitor. Galectin-3 is a protein that plays a key role in cell signaling, differentiation, apoptosis, and inflammation, the analyst tells investors in a research note. The firm says that despite the company’s setbacks, it believes “the stock can get back on track.” It says belapectin is a “unique therapy targeting a clinically relevant molecule.”